Cancer genetics of sporadic colorectal cancer: BRAF and PI3KCA mutations, their impact on signaling and novel targeted therapies

Anticancer Research

Volumn 26, Issue 2 A, 2006, Pages 1077-1084

  Oikonomou, Eftychia ^a   Pintzas, Alexandros ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

Author keywords

BRAF; BRAF inhibitors; Colorectal cancer (CRC); KRAS; Microarrays; Mutated gene signature; PI3KCA; Review

Indexed keywords

B RAF KINASE;

ADENOMA; CANCER GENETICS; CARCINOMA; COLORECTAL CANCER; GENE EXPRESSION; ONCOGENE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; COLORECTAL NEOPLASMS; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION;

EID: 33645812174     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Fearon ER and Vogelstein B: A genetic model for colorectal tumourigenesis. Cell 67: 759-767, 1990.
2. Ilyas M, Straub J, Tomlinson IP and Bodmer WF: Genetic pathways in colorectal and other cancers (Review). Eur J Cancer 14: 1986-2002, 1999.
3. Davies H, Bignell OR, Cox C et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
4. Velho S, Oliveira C, Ferreira A et al: The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 41: 1649-1654, 2005.
5. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD and Downward J: Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370: 527-532, 1994.
6. Kelley GG, Reks SE, Ondrako JM and Smrcka AV: Phospholipase C(epsilon): a novel Ras effector. EMBO J 20: 743-754, 2001.
7. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ and Vogelstein B: Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293-297, 1987.
8. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B and Velculescu VE: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561-573, 2005.
9. Cantley LC: The phosphoinositide 3-kinase pathway (Review). Science 296: 1655-1657, 2002.
10. Park J, Hill MM, Hess D, Brazil DP, Hofsteenge J and Hemmings BA: Identification of tyrosine phosphorylation sites on 3-phosphoinositide-dependent protein kinase-1 and their role in regulating kinase activity. J Biol Chem 276: 37459-37471, 2001.
11. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997.
12. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S and Reed JC: Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-1321, 1998.
13. Ciechomska I, Pyrzynska B, Kazmierczak P and Kaminska B: Inhibition of Akt kinase signalling and activation of forkhead are indispensable for upregulation of FasL expression in apoptosis of glioma cells. Oncogene 22: 7617-7627, 2003.
14. Dijkers PF, Medema RH, Lammers JW, Koenderman L and Coffer PJ: Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 10: 1201-1204, 2000.
15. Yang CH, Murti A, Pfeffer SR, Kim JG, Donner DB and Pfeffer LM: Interferon alpha/beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt. J Biol Chem 276: 13756-13761, 2001.
16. Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN and Rosen N: Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 275: 29864-29872, 1998.
17. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH and Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275: 1943-1947, 1997.
18. Testa JR and Bellacosa A: AKT plays a central role in tumourigenesis (Review). Proc Natl Acad Sci USA 98: 10983-10985, 2001.
19. Chan TO, Rodeck U, Chan AM, Kimmelman AC, Rittenhouse SE, Panayotou G and Tsichlis PN: Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell 1: 181-191, 2002.
20. Khaleghpour K, Li Y, Banville D, Yu Z and Shen SH: Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 25: 241-248, 2004.
21. Di Cristofano A, Pesce B, Cordon-Cardo C and Pandolfi PP: Pten is essential for embryonic development and tumour suppression. Nat Genet 19: 348-355, 1998.
22. Chang HW, Aoki M, Fruman D, Auger KR, Bellacosa A, Tsichlis PN, Cantley LC, Roberts TM and Vogt PK: Transformation of chicken cells by the gene encoding the catalytic subunit of PI3-kinase. Science 276: 1848-1850, 1997.
23. Dufour G, Demers MJ, Gagne D, Dydensborg AB, Teller IC, Bouchard V, Degongre I, Beaulieu JF, Cheng JQ, Fujita N, Tsuruo T, Vallee K and Vachon PH: Human intestinal epithelial cell survival and anoikis. Differentiation state - distinct regulation and roles of protein kinase B/Akt isoforms. J Biol Chem 279: 44113-44122, 2004.
24. Semba S, Itoh N, Ito M, Youssef EM, Harada M, Moriya T, Kimura W and Yamakawa M: Down-regulation of PIK3CG, a catalytic subunit of phosphatidylinositol 3-OH kinase, by CpG hypermethylation in human colorectal carcinoma. Clin Cancer Res 8: 3824-3831, 2002.
25. Bar J, Lukaschuk N, Zalcenstein A, Wilder S, Seger R and Oren M: The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis. Cell Death Differ Jun 3; Epub ahead of print, 2005.
26. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H and Sawyers CL: Enhanced sensitivity of PTEN-deficient tumours to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98: 10314-10319, 2001.
27. Zhang BH and Guan KL: Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J 19: 5429-5439, 2000.
28. Mason CS, Springer CJ, Cooper RG, Superti-Furga G, Marshall CJ and Marais R: Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J 18: 2137-2148, 1999.
29. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D and Marais R: Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855-867, 2004.
30. Lyons JF, Wilhelm S, Hibner B and Bollag G: Discovery of a novel Raf kinase inhibitor (Review). Endocr Relat Cancer 8: 219-225, 2001.
31. Weber CK, Slupsky JR, Kalmes HA and Rapp UR: Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res 61: 3595-3598, 2001.
32. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ and Marais R: B-RAF is a therapeutic target in melanoma. Oncogene 23: 6292-6298, 2004.
33. Dai Y, Yu C, Singh V, Tang L, Wang Z, McInistry R, Dent P and Grant S: Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 67: 5106-5115, 2001.
34. Weber CK, Slupsky JR, Kalmes HA and Rapp UR: Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res 61: 3595-3598, 2001.
35. Ikehara N, Semba S, Sakashita M, Aoyama N, Kasuga M and Yokozaki H: BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. Int J Cancer 115: 943-950, 2005.
36. Dai Q, Choy E, Chiu V, Romano J, Slivka SR, Steitz SA, Michaelis S and Philips MR: Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum. J Biol Chem 273: 15030-15034, 1998.
37. Li W, Zhu T and Guan KL: Transformation potential of Ras isoforms correlates with activation of phosphatidylinositol 3-kinase but not ERK. J Biol Chem 279: 37398-37406, 2004.
38. Bos JL: Ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689, 1989.
39. Antonny B, Chardin P, Roux M and Chabre M: GTP hydrolysis mechanisms in ras p21 and in the ras-GAP complex studied by fluorescence measurements on tryptophan mutants. Biochemistry 30: 8287-8295, 1991.
40. Feng M, Cabrera G, Deshane J, Scanlon KJ and Curiel DT: Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 55: 2024-2028, 1995.
41. Cooper S, Howard R, Glazer R, Trent K, Leamon CP, Mehta R, Ohashi C, Cowsert L, Monia BP and Dean NM: Liposome formulation improves efficacy against xenografted human tumour lines in nude mice, and alters pharmacokinetics of an antisense oligonucleotide inhibitor of H-ras expression. Proc Am Assoc Cancer Res 39: 417, 1998.
42. Cochet O, Kenigsberg M, Delumeau I, Virone-Oddos A, Multon MC, Fridman WH, Schweighoffer F, Teillaud JL and Tocqué B: Intracellular expression of an antibody fragment neutralizing p21ras promotes tumour regression. Cancer Res 58: 1170-1176, 1998.
43. Ura H, Obara T, Shudo R, Itoh A, Tanno S, Fujii T, Nishino N and Kohgo Y: Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts. Mol Carcinog 21: 93-99, 1998.
44. Smith V, Rowlands MG, Barrie E, Workman P and Kelland LR: Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Clin Cancer Res 8: 2002-2009, 2002.
45. LeBlanc HN and Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors (Review). Cell Death Differ 10: 66-75, 2003.
46. Drosopoulos KG, Roberts ML, Cermak L, Sasazuki T, Shirasawa S, Andera L and Pintzas A: Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J Biol Chem 280: 22856-22867, 2005.
47. Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL and Quon KC: Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 5: 501-512, 2004.
48. Roberts ML, Drosopoulos KG, Vasileiou I, Stricker M, Taoufik E. Maercker C, Guialis A, Alexis MN and Pintzas A: Microarray analysis of the differential transformation mediated by Kirsten and Harvey Ras oncogenes in a human colorectal adenocarcinoma cell line. Int J Cancer 118: 616-627, 2006.
49. Tullai JW, Schaffer ME, Mullenbrock S, Kasif S and Cooper GM: Identification of transcription factor binding sites upstream of human genes regulated by the phosphatidylinositol 3-kinase and MEK/ERK signaling pathways. J Biol Chem 279: 20167-20177, 2004.
50. Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, Walker GJ, Boyle GM, Harper U, Cozzi SJ, Hansen K, Yudt L, Schmidt C, Hersey P, Ellem KA, O'Rourke MG, Parsons PG, Meltzer P, Ringner M and Hayward NK: Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23: 4060-4067, 2004.
51. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, Gauger P, Doherty G, Thompson NW, Hanash S, Koenig RJ and Nikiforov YE: Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24: 6646-6656, 2005.